GIKLY - Grifols, S.A.
| Previous Close | 17.95 |
| Open | 17.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 17.95 - 17.95 |
| 52 Week Range | 12.85 - 17.95 |
| Volume | 38 |
| Avg. Volume | 104 |
| Market Cap | 20.725B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | 29.94 |
| EPS (TTM) | 0.60 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.22 (1.24%) |
| Ex-Dividend Date | Dec 01, 2019 |
| 1y Target Est | N/A |
- Simply Wall St.
Need To Know: Grifols, S.A. (BME:GRF) Insiders Have Been Buying Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- PR Newswire
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency (PI).
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Grifols SA (GRFS)
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
- PR Newswire
Grifols presents its latest Alzheimer's clinical trial data
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial with the presentation of new neuroimaging data that show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer's disease.
- PR Newswire
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced the launch of its latest sterile compounding technology, KIRO Fill®, as well as its next-generation software enhancements within the PharmacyKeeper IV workflow platform. The new updates will be showcased at the Grifols booth, 819, during the ASHP Midyear 2019 Clinical Meeting & Exhibition on December 8-12, 2019, at the Mandalay Bay Convention Center in Las Vegas.
- PR Newswire
Grifols to present latest Alzheimer's clinical trial results
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, Calif. (USA).
- Simply Wall St.
Is Grifols (BME:GRF) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- PR Newswire
Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD
BARCELONA, Spain, Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID™, a new, simple cheek swab that can be used by physicians to screen patients with chronic obstructive pulmonary disease (COPD) for alpha-1 antitrypsin deficiency (Alpha-1), a rare, life-threatening genetic condition.
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's affirms Grifols Ba3 CFR; outlook stable
Moody's Investors Service ("Moody's") has today affirmed the Ba3 corporate family rating (CFR), Ba3-PD probability of default rating (PDR), and B2 senior unsecured rating of Grifols S.A. (Grifols), a Spanish healthcare company primarily focused on human blood plasma-derived products and transfusion medicine. At the same time, Moody's has assigned a Ba2 rating to the proposed USD5.0 billion equivalent worth of senior bank facilities to be issued by Grifols, Grifols World Wide Operations Ltd., and Grifols Worldwide Operations USA, Inc., both wholly-owned subsidiaries of Grifols.
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) ROE Of 12% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Simply Wall St.
Is Grifols, S.A. (BME:GRF) Worth €27.10 Based On Its Intrinsic Value?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Grifols, S.A...
- Simply Wall St.
Should Grifols (BME:GRF) Be Disappointed With Their 61% Profit?
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) 1.2% Dividend Worth Your Time?
Is Grifols, S.A. (BME:GRF) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can...
- PR Newswire
Grifols presents additional encouraging Alzheimer's trial results at AAIC
BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).
- Simply Wall St.
How Much Are Grifols, S.A. (BME:GRF) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Investor's Business Daily
This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
- Benzinga
The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
- PR Newswire
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa
BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line. Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.
- PR Newswire
Grifols to launch plasma-protein-based bleeding-control solutions
BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.
- Motley Fool
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Simply Wall St.
Do Institutions Own Grifols, S.A. (BME:GRF) Shares?
Every investor in Grifols, S.A. (BME:GRF) should be aware of the most powerful shareholder groups. Insiders often own...
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's announces completion of a periodic review of ratings of Grifols S.A.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, May 16, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Motley FoolRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- PR Newswire
Grifols Announces PharmacyKeeper Bidirectional Integration with Epic
BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.
